MINO Labs Publishes First-Ever Human Clinical Trial Demonstrating Protective Benefits of CBD Cream Against UVA-Induced Skin Damage--Offering New Hope for Fighting Skin Cancer and Photoaging
New science and skincare innovation, CielementsMD® DNA Defense Daily Cream, works with sunscreen to prevent photoaging and lower skin cancer risk—with clinically-proven results.
NEW YORK, May 22, 2025 /PRNewswire/ -- MINO Labs, LLC ('MINO Labs'), a privately held specialty pharmaceutical company, is proud to announce the publication of a groundbreaking clinical study in the Journal of the American Academy of Dermatology (JAAD), highlighting the protective benefits of its patented CannaXR™ (extended release) cannabidiol (CBD) cream: DNA Defense Daily Cream.
As May marks Skin Cancer Awareness Month and 'Don't Fry Day' falls on May 23, this scientific milestone establishes a new category of sun protection at a crucial time of year for sun safety awareness—offering fresh hope in the fight against skin aging and sun-induced skin cancers.
The peer-reviewed study is the first-ever in-human clinical trial to demonstrate that a CBD-based topical can reduce Ultraviolet A (UVA)-induced DNA damage at the cellular level, preventing both nuclear and mitochondrial DNA mutations associated with accelerated skin aging and skin cancer.
'CBD has a volume of supporting evidence in the literature for enumerable skin benefits, however the translation to the bottle in your hand has been limited due to its ability to actually get into the skin. The innovative delivery system used in this product, Z-pods™, fills that gap and now allows us to take full advantage of the incredible potential CBD has to offer,' said Dr. Adam Friedman, Professor and Chair of Dermatology at The George Washington University School of Medicine and Health Sciences and co-inventor of the Z-pod™ technology.
The full study, titled 'Topical Nanoencapsulated Cannabidiol Cream as an Innovative Strategy Combating UVA-Induced Nuclear and Mitochondrial DNA Injury: A Pilot Randomized Clinical Study,' is available here: JAAD.
Key Findings from Clinical Trial (NCT05279495):
'This landmark study represents a major advance in dermatological protection and anti-aging science,' said Dr. Brian Berman, MD, PhD, principal investigator and past Vice President of the American Academy of Dermatology. 'With skin cancer still the most diagnosed cancer in the U.S., solutions like CannaXR™ that demonstrate molecular protection are a vital step forward.'
According to the U.S. Centers for Disease Control and Prevention, more than 6.1 million U.S. adults are treated annually for basal and squamous cell carcinoma, costing over $8.9 billion. UVA exposure plays a major role in this, accelerating both visible aging and DNA damage that can lead to cancer.
CannaXR™: Science Meets Skincare in the Fight Against Sun Damage
Developed by MINO Labs, CannaXR™ combines advanced nanotechnology and cannabidiol in a novel extended-release cream that may offer a new kind of topical protection—complementing sunscreen, but focused on reducing internal cellular damage 'Innovative drug delivery systems are key factors on effectiveness of each product' mentioned Manuel Cosme Odabachian, CEO of MINO Labs.
As we recognize Skin Cancer Awareness Month, MINO Labs is committed to driving awareness and offering evidence-based tools to help individuals better protect their skin and long-term health.
About MINO Labs
MINO Labs is a specialty pharmaceutical company leveraging two decades of dermatologic innovation to develop next-generation wellness and protective therapies. With a growing pipeline of nanotechnology-based products, MINO Labs is poised to transform how we protect and preserve skin health.
Learn more: www.cielementsmd.com
Contact:
Jennifer Fisherman-Ruff [email protected]
Carina Bonasera [email protected]
Emily Tindol [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/mino-labs-publishes-first-ever-human-clinical-trial-demonstrating-protective-benefits-of-cbd-cream-against-uva-induced-skin-damageoffering-new-hope-for-fighting-skin-cancer-and-photoaging-302450635.html
SOURCE MINO Labs
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT). Results demonstrated an overall response rate (ORR) of 87 percent, a complete response (CR) rate of 65 percent and a partial response (PR) of 23 percent. The majority of patients (65 percent) proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30 th European Hematology Association (EHA) 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome (CRS) being low grade and no discontinuations due to treatment-emergent adverse events (TEAEs). The most common TEAEs were neutropenia (74 percent), anemia (68 percent), and thrombocytopenia (68 percent). CRS occurred in 52 percent; all were low grade (1/2) and resolved. One patient had immune effector cell-associated neurotoxicity syndrome (ICANS; grade 1), which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients (58 percent); five (16 percent) had serious infections. There were no Grade 5 TEAEs. 'These results are particularly encouraging because many of the patients in this study had high-risk disease, having progressed rapidly after initial treatment,' said Raul Cordoba, MD, PhD, Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. 'This combination therapy of epcoritamab plus rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) offers a potential new treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma, providing high response rates and a bridge to potentially curative autologous stem cell transplantation." Among patients in the study who progressed within 12 months after first-line treatment (n=20), epcoritamab in combination with R-ICE demonstrated an 85 percent ORR and 55 percent CR. Patients in the study who progressed after 12 months from first-line therapy experienced a 91 percent ORR and 82 percent CR. Additionally, patients with one prior line of therapy experienced an 88 percent ORR and 68 percent CR, and patients who were treated with more than one prior line of therapy experienced an 83 percent ORR and 50 percent CR. 'The results from this trial highlight the potential of this investigational epcoritamab containing regimen, especially in patients who progress quickly after initial treatment, and reinforce our joint efforts with AbbVie to develop epcoritamab as a core therapy for B-cell lymphomas, especially as we develop epcoritamab in earlier lines of therapy and a broader patient population,' said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. 'Our comprehensive EPCORE clinical trial program is dedicated to advancing epcoritamab as both monotherapy and in combination to address the significant unmet need in relapsed/refractory diffuse large B-cell lymphoma and other hematologic malignancies." Use of epcoritamab + R-ICE in patients with R/R DLBCL eligible for ASCT is not approved and the safety and efficacy of epcoritamab for use as a combination therapy in DLBCL have not been established. About Diffuse Large B-Cell Lymphoma DLBCL is the most common type of non-Hodgkin's lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases. In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year. DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men. DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge. About the EPCORE ® NHL-2 Trial EPCORE NHL-2 is a Phase 1b/2 open-label interventional trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab as a monotherapy and in combination with other standard of care agents in patients with B-cell non-Hodgkin's lymphoma (B-NHL). The trial consists of two parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The primary objective of Part 1 is safety, and the primary goal of Part 2 is preliminary efficacy. The primary endpoint was overall response rate (ORR) based on best overall response per Lugano criteria. MRD negativity was assessed as a secondary endpoint. Arm 10 of the EPCORE NHL-2 study enrolled 31 patients with R/R DLBCL, who were eligible for R-ICE and ASCT, and had received ≥1 prior line of treatment. At the time of data cutoff (December 18, 2024), median follow-up was 11 months (range, 6−15). Among the 31 patients treated with epcoritamab 48 mg + R-ICE, 61 percent were Ann Arbor stage III/IV, 42 percent had bulky disease ≥7 cm, 81 percent had one prior LOT (range, 1−3), and 65 percent had progressed within 12 months of first-line treatment. More information on this trial can be found at (NCT: 04663347). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. i Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Where approved, epcoritamab is available as a readily accessible therapy without the need for reducing tumor burden ('debulking'). Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigators choice chemotherapy (NCT04628494), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with R/R FL (NCT05409066), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744), and a trial evaluating epcoritamab in combination with R2 compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit for more information. EPKINLY ® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. Important Warnings—EPKINLY can cause serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away. EPKINLY can cause other serious side effects, including: Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Full Prescribing Information and Medication Guide, including Important Warnings. Globally, prescribing information varies; refer to the individual country product label for complete information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ®) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and X. This Media Release contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody ®; DuoHexaBody ®, HexElect ® and KYSO™. EPCORE ®, EPKINLY ®, TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine
Newsweek
7 hours ago
- Newsweek
Vitamin Gummies Recalled Over Undeclared Peanut Allergen Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Vita Warehouse Corp. has voluntarily recalled three popular vitamin B12 gummy products due to potential undeclared peanut contamination, the U.S Food and Drug Administration (FDA) announced this week. Newsweek reached out to Vita Warehouse Corp. via email on Saturday for comment. Why It Matters Individuals who are allergic to peanuts have immune systems that react to peanuts, with symptoms that might include skin reactions, itching or tingling in the mouth or throat, digestive problems such as diarrhea, runny nose, tightening of the throat and shortness of breath. In severe cases, people with food allergies may go into anaphylaxis—and peanuts are the most common cause of anaphylactic allergic reactions. Anaphylaxis may involve difficulty breathing, swelling of the lips, tongue and throat, a drop in blood pressure, a rapid pulse, dizziness, lightheadedness or a loss of consciousness. June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™ Vitamin... June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™ Vitamin B12 Extra Strength 60 Gummies due to the potential presence of undeclared peanuts. More U.S. Food & Drug Administration/FDA What To Know The affected products include three distinct vitamin B12 formulations: Welby's 1000 mcg 140-count gummies in green, red, and white packaging (UPC: 4099100290868); Berkley Jensen's 1000 mcg 250-count gummies in red and pink labeling (UPC: 888670132487) VitaGlobe's Extra Strength 60-count gummies with white and red packaging (UPC: 850005214670) All products feature clear bottles with white caps, with lot codes and expiration dates printed on bottle bottoms. No illnesses or allergic reactions have been reported to date. Consumers should check these details before use, as only products with lot number 248046601 and October 2026 expiration dates are affected. The recall spans multiple distribution channels, including physical ALDI and BJ's locations nationwide, plus online sales through company websites and Amazon. Vita Warehouse Corp. emphasized that no other products under these brand names are affected by the recall. What People Are Saying Vita Warehouse Corp. Statement: "This voluntary recall was initiated out of an abundance of caution to ensure consumer safety and trust. We are committed to maintaining the highest product safety and quality standards." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™... June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™ Vitamin B12 Extra Strength 60 Gummies due to the potential presence of undeclared peanuts. More U.S. Food & Drug Administration/FDA What Happens Next Consumers who purchased affected products should immediately stop using them and return items to their place of purchase for full refunds or dispose of them safely. Those experiencing allergic reactions should seek immediate medical attention. Vita Warehouse Corp. has established a consumer hotline at 1-855-214-0100, operating Monday through Friday from 7:30 AM to 4:00 PM EST, to address customer questions and concerns.
Yahoo
a day ago
- Yahoo
Yesoul R1M PLUS Home Rowing Machine: A Full-Body Fitness Solution Designed for Men's Health and Everyday Life
HONG KONG, June 14, 2025 /PRNewswire/ -- Coinciding with Men's Health Month, Yesoul promotes accessible home fitness tailored for today's busy men—from young professionals to active retirees. Prioritizing Men's Health: Why It Matters More Than Ever June is recognized globally as Men's Health Month—a time dedicated to raising awareness about the physical and mental health challenges men face throughout their lives. From young professionals navigating demanding careers to fathers juggling family and work, and older men seeking longevity and vitality, men's wellness is a multifaceted issue that deserves year-round attention. Despite increasing public health campaigns, studies consistently show that men are less likely than women to seek medical advice, maintain regular fitness routines, or engage in preventive care. Factors such as time constraints, work-related stress, and cultural stigmas around masculinity contribute to rising rates of chronic illness, cardiovascular conditions, and mental health struggles. That's why accessible, tech-enhanced home fitness equipment—like the Yesoul R1 M PLUS Rowing Machine—is more essential than ever. Compact, versatile, and designed with real-life convenience in mind, the R1 M PLUS empowers men across all life stages to take control of their health, right from the comfort of their homes. The Yesoul R1 M PLUS: A Modern Rowing Machine Built for Real Life More than just a piece of exercise equipment, the R1 M PLUS is a wellness ally engineered for versatility, comfort, and intelligent fitness. With design elements tailored to support modern lifestyles, this machine helps eliminate common workout barriers, like time, space, and noise. Foldable Design That Fits Any Space One of the R1 M PLUS's standout features is its space-saving foldability. Whether you're in a city apartment, home office, or shared living area, its vertical-folding rail reduces the footprint by over 50%. Paired with smooth transport wheels, it's easy to roll the machine away when not in use—making it ideal for men with limited space or irregular routines. Full-Body, Low-Impact Workouts for All Fitness Levels Rowing is widely considered one of the most efficient full-body workouts, engaging over 80% of major muscle groups—legs, core, back, and arms—while being gentle on the joints. It's an ideal form of exercise for: Busy professionals looking to build stamina and reduce stress Dads fitting in workouts between family responsibilities Middle-aged men maintaining muscle tone and metabolic health Seniors who want a joint-friendly cardiovascular activity Silent Magnetic Resistance with 100 Intensity Levels The R1 M PLUS features a custom magnetic resistance system that delivers whisper-quiet operation with 100 adjustable levels, so users can tailor their workout intensity without disturbing others. Whether you prefer a relaxing endurance row or a sweat-inducing sprint session, this machine adapts to your goals without compromise. Immersive 21.5" Rotating Screen with Free Mirroring The heart of the R1 M PLUS experience is its 21.5-inch 1080p full HD screen. Designed to rotate 360°, it enables not only rowing sessions but also access to stretching, HIIT, yoga, and strength training classes—all in one place. A major highlight is the R1 M PLUS's Free & Unlimited Screen Mirroring feature. Without requiring any subscription, users can simply connect their devices (note: Android phones require DisplayPort support) and stream content directly onto the 21.5-inch rotating screen—from YouTube workouts to popular fitness apps like, Kinomap, or Zwift. This gives users the freedom to enjoy their favorite platforms, videos, or routines on a larger screen, completely free of charge. While some brands charge over $100 per year for app access, the Yesoul App remains affordable—offering a full library of workouts, real-time data tracking, and training features for less than the cost of a nice dinner out. And even without a subscription, users can still take full advantage of the screen mirroring feature to enhance their fitness experience at no cost. This flexibility empowers men to stay motivated and consistent while tracking workout data like stroke rate, power, distance, resistance, and calories—all from the comfort of home. Mental Fitness Matters, Too Modern masculinity means taking care of both body and mind. Rowing provides a meditative rhythm that promotes stress relief and mental clarity. Combined with scenic virtual routes or relaxing music streamed through the screen, the R1 M PLUS becomes a tool for both physical and emotional balance. Through the Yesoul app, users can enjoy mindfulness-based workouts, expert-led stretches, and calming cooldowns that promote relaxation and speed up recovery. Ergonomically Designed for Comfort, Strength, and Safety The R1 M PLUS features ergonomic handles, adjustable foot straps, and a sturdy yet minimalist frame. It's engineered to accommodate a wide range of body types and rowing styles while minimizing strain and maximizing comfort. Seamless Integration into Daily Life Quick Assembly: Easy-to-follow instructions get you started in minutes Minimalist Aesthetic: A sleek, neutral-toned design blends into modern interiors Flexible Training Modes: Rotate the screen for cross-training, stretching, or floor workouts Who Is It For? This rowing machine isn't just for one type of user. The R1 M PLUS was thoughtfully designed to support all men—across ages, goals, and lifestyles: Young Professionals: Maximize limited time with full-body workouts that boost energy and reduce sedentary stress Fathers: Stay strong, focused, and healthy with fast, effective at-home fitness Middle-Aged Men: Maintain strength, manage weight, and protect cardiovascular health as priorities shift Retirees: Improve balance, mobility, and longevity through safe, joint-friendly exercise Whether you're new to rowing or a seasoned athlete, the R1 M PLUS offers an inclusive path to consistent, long-term wellness. Yesoul's Broader Mission: Redefining Everyone By spotlighting the R1 M PLUS during Men's Health Month, Yesoul underscores its larger commitment to men's well-being. The brand is actively shifting fitness culture away from intimidation and exclusivity toward accessibility, comfort, and relevance. From smart bikes to treadmills to rowing machines, Yesoul is building an ecosystem that empowers men to prioritize self-care, redefine their health journeys, and access premium technology without premium pricing. It's More Than a Machine—It's a Mindset Shift In a world that often asks men to "tough it out," Yesoul is encouraging them to slow down, check in, and row forward—one stroke at a time. The R1 M PLUS makes fitness easier to begin, more enjoyable to maintain, and more adaptable to the realities of everyday life. Make Wellness a Year-Round Priority This June and beyond, take the next step toward better health with a tool that meets you where you are. The R1 M PLUS Rowing Machine isn't just equipment—it's a commitment to longevity, strength, and balance. Explore more at Follow Yesoul for tips, tutorials, and community stories: Instagram: @ @YESOUL FITNESS View original content to download multimedia: SOURCE Yesoul Fitness Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
